Celgene is known for making high-dollar bets for strategic assets. Arguably, from the statement by Bob Hugin on neurodegeneration R&D, Celgene may be about to skate to where the puck is going to be driven by the demographics of an ageing population.
So what does a high-dollar bet look like to secure a strategic pipeline deal? In order to provide a realistic comparison with Neuren lets only look only at companies with Phase 11 clinical results in hand.
Celgene acquired Receptos for US$7.2B in July 2015 in order to secure ozanimod which is in clinical trials for ulcerative colitis and multiple sclerosis. Now, that's a big bet even though to be fair Receptos has progressed to Phase 111 development. If successful, ozanimod could bring in peak annual sales of US$4-6B.
Hugin stated that the Receptos acquisition provided a transformational opportunity to impact multiple therapeutic areas in inflammation and immunology. Now what was he reported to have said about neurodegeneration R&D?
Outside Markets, page-9
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.52 |
Change
0.660(3.32%) |
Mkt cap ! $2.622B | |||
| Open | High | Low | Value | Volume |
| $20.00 | $20.66 | $19.94 | $6.431M | 315.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1024 | $20.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.53 | 285 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |